Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241938 | 0.84 | L3MBTL1 (0.58) | KMT2AEPHX2HSD11B1L3MBTL1FAAH | |
| SCHEMBL238713 | 0.83 | L3MBTL1 (0.57) | KMT2AEPHX2HSD11B1L3MBTL1CNR1 | |
| SCHEMBL1675968 | 0.83 | KMT2A (0.57) | KMT2AEPHX2HSD11B1L3MBTL1FAAH | |
| SCHEMBL19808151 | 0.83 | HSD11B1 (0.54) | KMT2AEPHX2HSD11B1L3MBTL1FAAH | |
| SCHEMBL1761711 | 0.82 | KMT2A (0.54) | KMT2AEPHX2FAAHCNR1CNR2 | |
| SCHEMBL14082229 | 0.82 | KMT2A (0.53) | KMT2AHSD11B1L3MBTL1FAAH | |
| SCHEMBL16530082 | 0.81 | HSD11B1 (0.57) | KMT2AEPHX2HSD11B1FAAH | |
| SCHEMBL1675970 | 0.81 | HSD11B1 (0.57) | KMT2AEPHX2HSD11B1FAAH | |
| SCHEMBL4608538 | 0.79 | KMT2A (0.54) | KMT2AEPHX2HSD11B1L3MBTL1CNR1 | |
| SCHEMBL4396722 | 0.79 | KMT2A (0.53) | KMT2AEPHX2HSD11B1L3MBTL1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3239131-A1 | NEW COMPOUNDS WITH ACTIVITY THAT PROTECTS AGAINST THE ACTION OF TOXINS AND VIRUSES IN INTRACELLULAR ACTION MODE | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2017-11-01 | — | — | EP | claimed |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | claimed |
| US-20160083355-A1 | COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2016-03-24 | — | — | US | claimed |
| US-8383381-B2 | Method for producing hydroxylated adaivjantane using cytochrome P450 | Shjonogi & Co., Ltd. (JP) | 2013-02-26 | — | — | US | claimed |
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-11-08 | — | — | US | claimed |
| US-20110086405-A1 | METHOD FOR PRODUCING HYDROXYLATED ADAMANTANE USING CYTOCHROME P450 | SHIONOGI & CO., LTD. (JP) | 2011-04-14 | — | — | US | claimed |
| CN-101878306-A | Method for producing hydroxylated adamantane using cytochrome P450 | SHIONOGI & CO | 2010-11-03 | — | — | CN | claimed |
| EP-2221380-A1 | METHOD FOR PRODUCING HYDROXYLATED ADAMANTANE USING CYTOCHROME P450 | Shionogi & Co., Ltd. (JP) | 2010-08-25 | — | — | EP | claimed |
| EP-2145873-A1 | New compounds with activity that protects against the action of toxins and viruses in intracellular action mode | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-01-20 | — | — | EP | claimed |
| CN-117050689-B | Preparation method and application of conductive polymer adhesive | 江苏理工学院 | 2024-03-19 | — | — | CN | disclosed |
| CN-117050689-A | Preparation method and application of conductive polymer adhesive | 江苏理工学院 | 2023-11-14 | — | — | CN | disclosed |
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| EP-3239131-A1 | NEW COMPOUNDS WITH ACTIVITY THAT PROTECTS AGAINST THE ACTION OF TOXINS AND VIRUSES IN INTRACELLULAR ACTION MODE | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2017-11-01 | — | — | EP | disclosed |
| CN-101878306-A | Method for producing hydroxylated adamantane using cytochrome P450 | SHIONOGI & CO | 2010-11-03 | — | — | CN | disclosed |
| EP-2221380-A1 | METHOD FOR PRODUCING HYDROXYLATED ADAMANTANE USING CYTOCHROME P450 | Shionogi & Co., Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-2221380-A1 | METHOD FOR PRODUCING HYDROXYLATED ADAMANTANE USING CYTOCHROME P450 | Shionogi & Co., Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-2145873-A1 | New compounds with activity that protects against the action of toxins and viruses in intracellular action mode | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-01-20 | — | — | EP | disclosed |
| EP-2145873-A1 | New compounds with activity that protects against the action of toxins and viruses in intracellular action mode | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-01-20 | — | — | EP | disclosed |
| WO-2009041470-A1 | METHOD FOR PRODUCING HYDROXYLATED ADAMANTANE USING CYTOCHROME P450 | SHIONOGI & CO., LTD. (JP) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | HAVCR2, MAVS, ANTXR2 | KMT2A 4248/4885EPHX2 4659/4885HSD11B1 4709/4885 |
| US-20160083355-A1 | COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION | HAVCR2, MAVS, ANTXR2 | KMT2A 4212/4885EPHX2 4690/4885HSD11B1 4746/4885 |
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | KMT2A 667/4885EPHX2 1124/4885HSD11B1 196/4885 |
| US-20110086405-A1 | METHOD FOR PRODUCING HYDROXYLATED ADAMANTANE USING CYTOCHROME P450 | CYP3A5, CYP1A2, POR | KMT2A 2915/4885EPHX2 88/4885HSD11B1 105/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | KMT2A 667/4885EPHX2 1124/4885HSD11B1 196/4885 |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | HAVCR2, MAVS, ANTXR2 | KMT2A 4212/4885EPHX2 4690/4885HSD11B1 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.